Clomid for Men: What the Evidence Does and Does Not Show

Nobody knows, and that is not a hedge - it is the finding. Clomiphene citrate raises testosterone and the two pituitary hormones above it, reliably and measurably. Whether that translates into a pregnancy has not been tested in a trial that qualifies for inclusion in a systematic review.

In 2026 a team at Aberdeen searched the literature to February 2025 for hormonal treatments in normogonadotropic men - men whose FSH and LH are already normal, which is most men with a poor semen result. Nine studies and 735 men met their criteria. Not one of them tested clomiphene. Not one tested an aromatase inhibitor. Tamoxifen, the other anti-oestrogen used the same way, showed no benefit; so did injected hCG with hMG.

A separate 2025 review did find ten randomised trials of clomiphene or tamoxifen against placebo in idiopathic male subfertility. Pooled, roughly one man in ten on clomiphene achieved a pregnancy against roughly one in fourteen on placebo - a difference so imprecisely estimated that the confidence interval runs from a large harm to a large benefit. The honest reading is that the question is open, not that the answer is yes.

Because of one genuinely good reason and one weaker one.

The good reason is that the obvious-looking alternative is worse. A man with low testosterone who is given testosterone gets his levels fixed and his sperm production switched off, because the brain reads the testosterone in his blood and stops sending the signals the testes need. The Endocrine Society's 2018 guideline recommends against starting testosterone therapy in men who are planning fertility in the near term. Clomiphene works the other way round: it blocks oestrogen feedback at the hypothalamus, so the pituitary sends more LH and FSH, and the testes make more of their own testosterone. Sperm production is left in place rather than suppressed.

The weaker reason is that it is a cheap tablet in a situation where the alternatives are expensive and invasive. Indian couples seeking non-IVF infertility care at tertiary centres reported median annual out-of-pocket spending of about Rs 13,211 where male infertility was the diagnosis, and nearly six in ten couples in that ICMR study met the definition of catastrophic health expenditure. Against an IVF-ICSI cycle, a strip of tablets looks like an obvious thing to try first. That is a reasonable instinct. It is not evidence.

If the question behind the prescription is really low testosterone rather than fertility, the two are worth keeping apart - see testosterone replacement therapy: pros and cons and the role of testosterone in male fertility.

It changes numbers on a blood test. LH rises, FSH rises, total testosterone rises. Those effects are consistent enough that they are not really in dispute, and they are what a prescriber will point to at the follow-up visit.

Three things do not follow from that:

• A better semen result. The 2026 review could not assess clomiphene's effect on semen quality because no eligible trial measured it. Of the hormonal treatments it could assess, only FSH injections produced measurable semen changes, and the reviewers called the benefits modest and short-term.
• A pregnancy. Sperm count and motility are surrogates. The outcome a couple wants is a baby, and the 10-trial pooled estimate for pregnancy is compatible with no effect.
• A live birth. No trial retrieved for this article reported live birth for clomiphene in men. That is the single largest gap in the evidence, and it is not closed by any amount of hormonal improvement.

The Clomid label says the same thing in its own words, in the Precautions section: there are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. That sentence has been in the label for decades. It is not an oversight waiting to be corrected.

A small and specific group: men whose pituitary genuinely is not sending the signal. Hypogonadotropic hypogonadism means low testosterone with low, not high, LH and FSH. Here the missing hormones can be replaced by injection, and sperm production can be started from nothing.

Even here the numbers deserve to be said plainly. Across 41 studies and 1,673 men, mean age 25, treated for a median of 18 months, sperm appeared in the ejaculate in about four men in five. Concentrations closer to what is usually needed for a natural conception were less common: roughly one man in four reached above 10 million per mL. Combined hCG with FSH did better than hCG alone.

The distinction matters because it is the one the live version of this page blurred. Clomiphene depends on a pituitary that can respond. Where FSH and LH are already high - the testes are being shouted at and not answering - pushing the signal higher has nothing left to recruit.

Which is why the blood tests come before the prescription, not after it: see FSH and LH in male infertility.

Not on the strength of a web page, and not without saying so to the person who prescribed it. There are legitimate reasons a urologist or andrologist prescribes clomiphene to a man - documented low testosterone with an intact pituitary, a wish to avoid testosterone while trying to conceive, a defined trial period with an end date. Stopping abruptly on your own removes any chance of finding out whether it did anything for you.

What is reasonable is to go back with better questions. An off-label prescription is not a wrong prescription; it is one where the reason has to be individual, because the licence does not supply it. Asking your doctor to say what this drug is expected to change in your case, and by when, is a normal part of that conversation.

It is worth naming how this feels. Being handed a tablet after months of waiting is a relief, and reading that the trials are missing takes that relief away without giving anything back. The point of knowing it is narrower than that: it lets you ask for a stop date instead of drifting through a year of repeat prescriptions.

There is no approved dose or monitoring schedule for men, because there is no approved use in men. Anything a prescriber does here is their own protocol, which is exactly why it is worth having it said out loud.

Questions that get a useful answer:

• What are my baseline numbers - total testosterone, LH, FSH, and a semen analysis - and when will each be repeated?
• What change would count as this working, and what change would count as it not working?
• When do we stop? A defined end date is the difference between a trial of treatment and an open-ended prescription.
• What are we doing about my partner's assessment in parallel, rather than sequentially?
• If my FSH and LH are already high, what is the reasoning for this drug specifically?

Two label warnings are worth knowing before the first tablet. Visual symptoms - blurring, spots, flashes - increase in incidence with increasing total dose or duration of therapy, are usually reversible, but have been reported to persist. Report them rather than pushing through. Separately, the label records testicular tumours and gynaecomastia in males taking clomiphene, noting that the cause-and-effect relationship is not known. That is an unresolved signal rather than a demonstrated harm, and it belongs in the conversation.

Set out plainly, because the rest of the internet on this topic does not:

• That clomiphene improves semen quality in men. No eligible trial in the 2026 review measured it.
• That clomiphene increases pregnancies. The pooled estimate from 10 randomised trials is compatible with no effect in either direction.
• That clomiphene increases live births. No retrieved trial reported this outcome for clomiphene in men at all.
• That aromatase inhibitors are a working alternative. The same 2026 review found no eligible studies of those either.
• That the older Cochrane review settles it. Cochrane withdrew "Clomiphene or tamoxifen for idiopathic oligo/asthenospermia" in 2007; the record now reads WITHDRAWN. Citations to it as live evidence are citations to a withdrawn document.
• That the testicular-tumour reports in the label represent a real risk. The label itself says causality is not known. Neither established nor excluded.

Sometimes the answer is not a drug at all. A poor semen result with normal hormones may be better served by repeating the test properly, looking for a treatable cause, or moving to IUI or ICSI with the sperm that are there - decisions that depend on the couple, not on the tablet.